Зміни

              
    

          
          
        
        

            
f
1
{
f
1
{
            
2
  "author": "Spravato Esketamine 56mg",
2
  "author": "Spravato Esketamine 56mg",
            
3
  "author_email": "inquiries.lyfeunit@proton.me",
3
  "author_email": "inquiries.lyfeunit@proton.me",
            
4
  "creator_user_id": "5ecc116b-5ec4-48f4-8366-afe5052790b1",
4
  "creator_user_id": "5ecc116b-5ec4-48f4-8366-afe5052790b1",
            
5
  "extras": [],
5
  "extras": [],
            
6
  "groups": [],
6
  "groups": [],
            
7
  "id": "5bc0de6f-a47a-4e87-882f-013470014d94",
7
  "id": "5bc0de6f-a47a-4e87-882f-013470014d94",
            
8
  "isopen": false,
8
  "isopen": false,
            
9
  "license_id": "",
9
  "license_id": "",
            
10
  "license_title": "",
10
  "license_title": "",
            
11
  "maintainer": "",
11
  "maintainer": "",
            
12
  "maintainer_email": "",
12
  "maintainer_email": "",
            
13
  "metadata_created": "2026-06-26T16:30:25.418385",
13
  "metadata_created": "2026-06-26T16:30:25.418385",
            
n
14
  "metadata_modified": "2026-06-26T16:31:59.550013",
n
14
  "metadata_modified": "2026-06-26T16:31:59.702712",
            
15
  "name": 
15
  "name": 
            
16
avato-esketamine-56mg-nasal-spray-dose-kit-fda-approved-trd-research",
16
avato-esketamine-56mg-nasal-spray-dose-kit-fda-approved-trd-research",
            
17
  "notes": "This dataset provides a comprehensive technical and 
17
  "notes": "This dataset provides a comprehensive technical and 
            
18
clinical overview of Spravato (Esketamine) 56mg Nasal Spray, the first 
18
clinical overview of Spravato (Esketamine) 56mg Nasal Spray, the first 
            
19
FDA-approved nasal treatment for treatment-resistant depression (TRD). 
19
FDA-approved nasal treatment for treatment-resistant depression (TRD). 
            
20
Each dose kit contains two 28mg single-use devices, delivering a 
20
Each dose kit contains two 28mg single-use devices, delivering a 
            
21
pharmaceutical-grade formulation that targets the brain\u2019s NMDA 
21
pharmaceutical-grade formulation that targets the brain\u2019s NMDA 
            
22
receptors to promote rapid synaptogenesis. This data is essential for 
22
receptors to promote rapid synaptogenesis. This data is essential for 
            
23
researchers at NIASRA and the University of Wollongong (UOW) focused 
23
researchers at NIASRA and the University of Wollongong (UOW) focused 
            
24
on interventional psychiatry and neuroplasticity.\r\n\r\nTechnical 
24
on interventional psychiatry and neuroplasticity.\r\n\r\nTechnical 
            
25
Specifications\r\n\t\u2022\tActive Ingredient: Esketamine (the 
25
Specifications\r\n\t\u2022\tActive Ingredient: Esketamine (the 
            
26
S-enantiomer of ketamine)\r\n\t\u2022\tConcentration: 28mg per device 
26
S-enantiomer of ketamine)\r\n\t\u2022\tConcentration: 28mg per device 
            
27
(56mg total per Dose Kit)\r\n\t\u2022\tMechanism: Non-competitive NMDA 
27
(56mg total per Dose Kit)\r\n\t\u2022\tMechanism: Non-competitive NMDA 
            
28
receptor antagonist\r\n\t\u2022\tRegulatory Status: FDA-Approved for 
28
receptor antagonist\r\n\t\u2022\tRegulatory Status: FDA-Approved for 
            
29
TRD and suicidal ideation\r\n\t\u2022\tDelivery Method: Intranasal 
29
TRD and suicidal ideation\r\n\t\u2022\tDelivery Method: Intranasal 
            
30
(Single-use devices)\r\n\r\nClinical & Research 
30
(Single-use devices)\r\n\r\nClinical & Research 
            
31
Applications\r\n\t\u2022\tRapid Antidepressant Effects: Investigating 
31
Applications\r\n\t\u2022\tRapid Antidepressant Effects: Investigating 
            
32
symptom relief timelines, often observed within 24 hours of 
32
symptom relief timelines, often observed within 24 hours of 
            
33
administration.\r\n\t\u2022\tNeuroplasticity & Synaptogenesis: 
33
administration.\r\n\t\u2022\tNeuroplasticity & Synaptogenesis: 
            
34
Exploring the modulation of glutamate receptors to restore neural 
34
Exploring the modulation of glutamate receptors to restore neural 
            
35
connections.\r\n\t\u2022\tTreatment-Resistant Depression (TRD): 
35
connections.\r\n\t\u2022\tTreatment-Resistant Depression (TRD): 
            
36
Analyzing efficacy in patients who have failed to respond to at least 
36
Analyzing efficacy in patients who have failed to respond to at least 
            
37
two different oral antidepressants.\r\n\t\u2022\tCo-Occurring Anxiety: 
37
two different oral antidepressants.\r\n\t\u2022\tCo-Occurring Anxiety: 
            
38
Researching the secondary benefits of esketamine in reducing anxiety 
38
Researching the secondary benefits of esketamine in reducing anxiety 
            
39
levels through neural pathway \u201cresetting.\u201d\r\n\r\nPatient 
39
levels through neural pathway \u201cresetting.\u201d\r\n\r\nPatient 
            
40
Experience & Safety Data\r\n\t\u2022\tDissociative Effects: 
40
Experience & Safety Data\r\n\t\u2022\tDissociative Effects: 
            
41
Documenting the temporary state of dissociation and sensory changes 
41
Documenting the temporary state of dissociation and sensory changes 
            
42
peaking at 40 minutes post-administration.\r\n\t\u2022\tMonitoring 
42
peaking at 40 minutes post-administration.\r\n\t\u2022\tMonitoring 
            
43
Protocols: Analyzing the importance of post-administration observation 
43
Protocols: Analyzing the importance of post-administration observation 
            
44
for blood pressure and sedation.\r\n\t\u2022\tDuration of Relief: 
44
for blood pressure and sedation.\r\n\t\u2022\tDuration of Relief: 
            
45
Tracking the enduring antidepressant benefits versus the short-lived 
45
Tracking the enduring antidepressant benefits versus the short-lived 
            
46
acute effects.\r\n\r\nSource Information\r\nFor detailed clinical data 
46
acute effects.\r\n\r\nSource Information\r\nFor detailed clinical data 
            
47
and pharmaceutical-grade procurement, 
47
and pharmaceutical-grade procurement, 
            
48
eunit.com/product/spravato-esketamine-56mg-nasal-spray-dose-kit/\r\n",
48
eunit.com/product/spravato-esketamine-56mg-nasal-spray-dose-kit/\r\n",
            
49
  "num_resources": 1,
49
  "num_resources": 1,
            
50
  "num_tags": 17,
50
  "num_tags": 17,
            
51
  "organization": null,
51
  "organization": null,
            
52
  "owner_org": null,
52
  "owner_org": null,
            
53
  "private": false,
53
  "private": false,
            
54
  "relationships_as_object": [],
54
  "relationships_as_object": [],
            
55
  "relationships_as_subject": [],
55
  "relationships_as_subject": [],
            
56
  "resources": [
56
  "resources": [
            
57
    {
57
    {
            
58
      "cache_last_updated": null,
58
      "cache_last_updated": null,
            
59
      "cache_url": null,
59
      "cache_url": null,
            
60
      "created": "2026-06-26T16:31:59.575053",
60
      "created": "2026-06-26T16:31:59.575053",
            
61
      "datastore_active": false,
61
      "datastore_active": false,
            
62
      "description": "This dataset captures the breakthrough clinical 
62
      "description": "This dataset captures the breakthrough clinical 
            
63
data associated with the Spravato (Esketamine) 56mg Nasal Spray Dose 
63
data associated with the Spravato (Esketamine) 56mg Nasal Spray Dose 
            
64
Kit. As a revolutionary alternative to traditional SSRIs and SNRIs, 
64
Kit. As a revolutionary alternative to traditional SSRIs and SNRIs, 
            
65
Spravato represents a paradigm shift in mental health treatment. The 
65
Spravato represents a paradigm shift in mental health treatment. The 
            
66
dataset is meticulously curated to align with the analytical standards 
66
dataset is meticulously curated to align with the analytical standards 
            
67
of the National Institute for Applied Statistics Research Australia 
67
of the National Institute for Applied Statistics Research Australia 
            
68
(NIASRA) and the University of Wollongong (UOW), providing a robust 
68
(NIASRA) and the University of Wollongong (UOW), providing a robust 
            
69
foundation for studying rapid-acting psychiatric 
69
foundation for studying rapid-acting psychiatric 
            
70
interventions.\r\n\r\nClinical & Technical Significance\r\nThe 
70
interventions.\r\n\r\nClinical & Technical Significance\r\nThe 
            
71
information detailed in this dataset is pivotal 
71
information detailed in this dataset is pivotal 
            
72
for:\r\n\r\n\t\u2022\tGlutamate System Modulation: Understanding how 
72
for:\r\n\r\n\t\u2022\tGlutamate System Modulation: Understanding how 
            
73
targeting the brain\u2019s most abundant excitatory neurotransmitter 
73
targeting the brain\u2019s most abundant excitatory neurotransmitter 
            
74
can \u201creset\u201d overactive anxious 
74
can \u201creset\u201d overactive anxious 
            
75
states.\r\n\t\u2022\tPrecision Dosing Analysis: Evaluating the 
75
states.\r\n\t\u2022\tPrecision Dosing Analysis: Evaluating the 
            
76
efficacy of the 56mg dose kit (2x28mg devices) in maintaining 
76
efficacy of the 56mg dose kit (2x28mg devices) in maintaining 
            
77
consistent therapeutic levels.\r\n\t\u2022\tLong-Term Remission 
77
consistent therapeutic levels.\r\n\t\u2022\tLong-Term Remission 
            
78
Studies: Providing data for the transition from induction phases to 
78
Studies: Providing data for the transition from induction phases to 
            
79
weekly or bi-weekly maintenance sessions.\r\n",
79
weekly or bi-weekly maintenance sessions.\r\n",
            
80
      "format": "JPEG",
80
      "format": "JPEG",
            
81
      "hash": "",
81
      "hash": "",
            
82
      "id": "002ec3cc-d7ee-4c27-9ed8-c93b0d44e23f",
82
      "id": "002ec3cc-d7ee-4c27-9ed8-c93b0d44e23f",
            
83
      "last_modified": "2026-06-26T16:31:59.545308",
83
      "last_modified": "2026-06-26T16:31:59.545308",
            
n
84
      "metadata_modified": "2026-06-26T16:31:59.556872",
n
84
      "metadata_modified": "2026-06-26T16:31:59.706250",
            
85
      "mimetype": "image/jpeg",
85
      "mimetype": "image/jpeg",
            
86
      "mimetype_inner": null,
86
      "mimetype_inner": null,
            
87
      "name": "Spravato (Esketamine) 56mg Nasal Spray Dose Kit 
87
      "name": "Spravato (Esketamine) 56mg Nasal Spray Dose Kit 
            
88
Research Data",
88
Research Data",
            
89
      "package_id": "5bc0de6f-a47a-4e87-882f-013470014d94",
89
      "package_id": "5bc0de6f-a47a-4e87-882f-013470014d94",
            
90
      "position": 0,
90
      "position": 0,
            
91
      "resource_type": null,
91
      "resource_type": null,
            
92
      "size": 18286,
92
      "size": 18286,
            
93
      "state": "active",
93
      "state": "active",
            
94
      "url": 
94
      "url": 
            
95
amine-nasal-spray-56-mg-dose-kit-2x28-ml-e1770733850318-400x400.jpeg",
95
amine-nasal-spray-56-mg-dose-kit-2x28-ml-e1770733850318-400x400.jpeg",
            
96
      "url_type": "upload"
96
      "url_type": "upload"
            
97
    }
97
    }
            
98
  ],
98
  ],
            
t
99
  "state": "draft",
t
99
  "state": "active",
            
100
  "tags": [
100
  "tags": [
            
101
    {
101
    {
            
102
      "display_name": "56mg Dose Kit",
102
      "display_name": "56mg Dose Kit",
            
103
      "id": "ef093861-cb71-48be-b875-e0417e514a65",
103
      "id": "ef093861-cb71-48be-b875-e0417e514a65",
            
104
      "name": "56mg Dose Kit",
104
      "name": "56mg Dose Kit",
            
105
      "state": "active",
105
      "state": "active",
            
106
      "vocabulary_id": null
106
      "vocabulary_id": null
            
107
    },
107
    },
            
108
    {
108
    {
            
109
      "display_name": "Data",
109
      "display_name": "Data",
            
110
      "id": "e0872c47-a8dc-4845-9d19-7cf661eb6120",
110
      "id": "e0872c47-a8dc-4845-9d19-7cf661eb6120",
            
111
      "name": "Data",
111
      "name": "Data",
            
112
      "state": "active",
112
      "state": "active",
            
113
      "vocabulary_id": null
113
      "vocabulary_id": null
            
114
    },
114
    },
            
115
    {
115
    {
            
116
      "display_name": "Esketamine",
116
      "display_name": "Esketamine",
            
117
      "id": "c2d35c54-8060-4ef2-85da-4c97f0ba10b9",
117
      "id": "c2d35c54-8060-4ef2-85da-4c97f0ba10b9",
            
118
      "name": "Esketamine",
118
      "name": "Esketamine",
            
119
      "state": "active",
119
      "state": "active",
            
120
      "vocabulary_id": null
120
      "vocabulary_id": null
            
121
    },
121
    },
            
122
    {
122
    {
            
123
      "display_name": "FDA-Approved",
123
      "display_name": "FDA-Approved",
            
124
      "id": "57d515d8-e9dd-49c7-b1a6-377b2de8d4cb",
124
      "id": "57d515d8-e9dd-49c7-b1a6-377b2de8d4cb",
            
125
      "name": "FDA-Approved",
125
      "name": "FDA-Approved",
            
126
      "state": "active",
126
      "state": "active",
            
127
      "vocabulary_id": null
127
      "vocabulary_id": null
            
128
    },
128
    },
            
129
    {
129
    {
            
130
      "display_name": "Mental Health",
130
      "display_name": "Mental Health",
            
131
      "id": "5d2277dd-ad41-4349-835d-af9d73cda788",
131
      "id": "5d2277dd-ad41-4349-835d-af9d73cda788",
            
132
      "name": "Mental Health",
132
      "name": "Mental Health",
            
133
      "state": "active",
133
      "state": "active",
            
134
      "vocabulary_id": null
134
      "vocabulary_id": null
            
135
    },
135
    },
            
136
    {
136
    {
            
137
      "display_name": "NIASRA",
137
      "display_name": "NIASRA",
            
138
      "id": "1b4af2e3-493f-4ee9-bfbc-30d31a49f0bf",
138
      "id": "1b4af2e3-493f-4ee9-bfbc-30d31a49f0bf",
            
139
      "name": "NIASRA",
139
      "name": "NIASRA",
            
140
      "state": "active",
140
      "state": "active",
            
141
      "vocabulary_id": null
141
      "vocabulary_id": null
            
142
    },
142
    },
            
143
    {
143
    {
            
144
      "display_name": "NMDA Antagonist",
144
      "display_name": "NMDA Antagonist",
            
145
      "id": "a63f032f-29d9-4d47-9122-7161fecfb948",
145
      "id": "a63f032f-29d9-4d47-9122-7161fecfb948",
            
146
      "name": "NMDA Antagonist",
146
      "name": "NMDA Antagonist",
            
147
      "state": "active",
147
      "state": "active",
            
148
      "vocabulary_id": null
148
      "vocabulary_id": null
            
149
    },
149
    },
            
150
    {
150
    {
            
151
      "display_name": "Nasal Spray",
151
      "display_name": "Nasal Spray",
            
152
      "id": "0bfb1408-7edb-4ef1-a87c-23682766ebfb",
152
      "id": "0bfb1408-7edb-4ef1-a87c-23682766ebfb",
            
153
      "name": "Nasal Spray",
153
      "name": "Nasal Spray",
            
154
      "state": "active",
154
      "state": "active",
            
155
      "vocabulary_id": null
155
      "vocabulary_id": null
            
156
    },
156
    },
            
157
    {
157
    {
            
158
      "display_name": "Neuroplasticity",
158
      "display_name": "Neuroplasticity",
            
159
      "id": "10d587ec-b7b0-42f0-813f-44faf92d46ca",
159
      "id": "10d587ec-b7b0-42f0-813f-44faf92d46ca",
            
160
      "name": "Neuroplasticity",
160
      "name": "Neuroplasticity",
            
161
      "state": "active",
161
      "state": "active",
            
162
      "vocabulary_id": null
162
      "vocabulary_id": null
            
163
    },
163
    },
            
164
    {
164
    {
            
165
      "display_name": "Psychiatry",
165
      "display_name": "Psychiatry",
            
166
      "id": "fe3d9ff9-abe6-4132-b550-467f06299dcf",
166
      "id": "fe3d9ff9-abe6-4132-b550-467f06299dcf",
            
167
      "name": "Psychiatry",
167
      "name": "Psychiatry",
            
168
      "state": "active",
168
      "state": "active",
            
169
      "vocabulary_id": null
169
      "vocabulary_id": null
            
170
    },
170
    },
            
171
    {
171
    {
            
172
      "display_name": "Spravato",
172
      "display_name": "Spravato",
            
173
      "id": "24f62ad1-d44a-4420-8fda-57da6bb2fd98",
173
      "id": "24f62ad1-d44a-4420-8fda-57da6bb2fd98",
            
174
      "name": "Spravato",
174
      "name": "Spravato",
            
175
      "state": "active",
175
      "state": "active",
            
176
      "vocabulary_id": null
176
      "vocabulary_id": null
            
177
    },
177
    },
            
178
    {
178
    {
            
179
      "display_name": "Synaptogenesis",
179
      "display_name": "Synaptogenesis",
            
180
      "id": "cc4b069d-294a-49bd-93c2-b8a4f660ab6c",
180
      "id": "cc4b069d-294a-49bd-93c2-b8a4f660ab6c",
            
181
      "name": "Synaptogenesis",
181
      "name": "Synaptogenesis",
            
182
      "state": "active",
182
      "state": "active",
            
183
      "vocabulary_id": null
183
      "vocabulary_id": null
            
184
    },
184
    },
            
185
    {
185
    {
            
186
      "display_name": "TRD",
186
      "display_name": "TRD",
            
187
      "id": "81d5c1b7-c410-47b5-9767-9995ba400ee4",
187
      "id": "81d5c1b7-c410-47b5-9767-9995ba400ee4",
            
188
      "name": "TRD",
188
      "name": "TRD",
            
189
      "state": "active",
189
      "state": "active",
            
190
      "vocabulary_id": null
190
      "vocabulary_id": null
            
191
    },
191
    },
            
192
    {
192
    {
            
193
      "display_name": "Treatment-Resistant Depression",
193
      "display_name": "Treatment-Resistant Depression",
            
194
      "id": "41c0476b-7f43-43d8-839b-71371434d332",
194
      "id": "41c0476b-7f43-43d8-839b-71371434d332",
            
195
      "name": "Treatment-Resistant Depression",
195
      "name": "Treatment-Resistant Depression",
            
196
      "state": "active",
196
      "state": "active",
            
197
      "vocabulary_id": null
197
      "vocabulary_id": null
            
198
    },
198
    },
            
199
    {
199
    {
            
200
      "display_name": "UOW",
200
      "display_name": "UOW",
            
201
      "id": "db7fb5f3-4f8e-45eb-ac60-18d37318f122",
201
      "id": "db7fb5f3-4f8e-45eb-ac60-18d37318f122",
            
202
      "name": "UOW",
202
      "name": "UOW",
            
203
      "state": "active",
203
      "state": "active",
            
204
      "vocabulary_id": null
204
      "vocabulary_id": null
            
205
    },
205
    },
            
206
    {
206
    {
            
207
      "display_name": "lyfeunit",
207
      "display_name": "lyfeunit",
            
208
      "id": "5f93ecf9-525c-486c-9f6c-877520686211",
208
      "id": "5f93ecf9-525c-486c-9f6c-877520686211",
            
209
      "name": "lyfeunit",
209
      "name": "lyfeunit",
            
210
      "state": "active",
210
      "state": "active",
            
211
      "vocabulary_id": null
211
      "vocabulary_id": null
            
212
    },
212
    },
            
213
    {
213
    {
            
214
      "display_name": "lyfeunit research",
214
      "display_name": "lyfeunit research",
            
215
      "id": "19ba78c1-042d-4d62-bfbe-1bf4bf3d27f2",
215
      "id": "19ba78c1-042d-4d62-bfbe-1bf4bf3d27f2",
            
216
      "name": "lyfeunit research",
216
      "name": "lyfeunit research",
            
217
      "state": "active",
217
      "state": "active",
            
218
      "vocabulary_id": null
218
      "vocabulary_id": null
            
219
    }
219
    }
            
220
  ],
220
  ],
            
221
  "title": "Spravato (Esketamine) 56mg Nasal Spray Dose Kit: 
221
  "title": "Spravato (Esketamine) 56mg Nasal Spray Dose Kit: 
            
222
FDA-Approved Data for Treatment-Resistant Depression",
222
FDA-Approved Data for Treatment-Resistant Depression",
            
223
  "type": "dataset",
223
  "type": "dataset",
            
224
  "url": 
224
  "url": 
            
225
/lyfeunit.com/product/spravato-esketamine-56mg-nasal-spray-dose-kit/",
225
/lyfeunit.com/product/spravato-esketamine-56mg-nasal-spray-dose-kit/",
            
226
  "version": ""
226
  "version": ""
            
227
}
227
}